

University of Groningen

## **Thinner Medial Temporal Cortex in Adolescents With Attention-Deficit/Hyperactivity Disorder and the Effects of Stimulants**

Schweren, Lizanne J. S.; Hartman, Catharina A.; Heslenfeld, Dirk J.; van der Meer, Dennis; Franke, Barbara; Oosterlaan, Jaap; Buitelaar, Jan K.; Faraone, Stephen V.; Hoekstra, Pieter J.

*Published in:*

Journal of the American Academy of Child and Adolescent Psychiatry

*DOI:*

[10.1016/j.jaac.2015.05.014](https://doi.org/10.1016/j.jaac.2015.05.014)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Final author's version (accepted by publisher, after peer review)

*Publication date:*

2015

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Schweren, L. J. S., Hartman, C. A., Heslenfeld, D. J., van der Meer, D., Franke, B., Oosterlaan, J., Buitelaar, J. K., Faraone, S. V., & Hoekstra, P. J. (2015). Thinner Medial Temporal Cortex in Adolescents With Attention-Deficit/Hyperactivity Disorder and the Effects of Stimulants. *Journal of the American Academy of Child and Adolescent Psychiatry*, 54(8), 660-667. <https://doi.org/10.1016/j.jaac.2015.05.014>

### **Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### **Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

# Accepted Manuscript

Thinner Medial Temporal Cortex in Adolescents With Attention-Deficit/Hyperactivity Disorder and the Effects of Stimulants

Lizanne J.S. Schweren, MSc, Catharina A. Hartman, PhD, Dirk J. Heslenfeld, PhD, Dennis van der Meer, MSc, Barbara Franke, PhD, Jaap Oosterlaan, PhD, Jan K. Buitelaar, MD, PhD, Stephen V. Faraone, PhD, Pieter J. Hoekstra, MD, PhD

PII: S0890-8567(15)00353-6

DOI: [10.1016/j.jaac.2015.05.014](https://doi.org/10.1016/j.jaac.2015.05.014)

Reference: JAAC 1228

To appear in: *Journal of the American Academy of Child & Adolescent Psychiatry*


Received Date: 27 November 2014

Revised Date: 28 May 2015

Accepted Date: 29 May 2015

Please cite this article as: Schweren LJS, Hartman CA, Heslenfeld DJ, van der Meer D, Franke B, Oosterlaan J, Buitelaar JK, Faraone SV, Hoekstra PJ, Thinner Medial Temporal Cortex in Adolescents With Attention-Deficit/Hyperactivity Disorder and the Effects of Stimulants, *Journal of the American Academy of Child & Adolescent Psychiatry* (2015), doi: 10.1016/j.jaac.2015.05.014.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Thinner Medial Temporal Cortex in Adolescents With Attention-Deficit/Hyperactivity Disorder and the Effects of Stimulants

RH = Cortical Thickness in Adolescent ADHD

Lizanne J.S. Schweren, MSc; Catharina A. Hartman, PhD; Dirk J. Heslenfeld, PhD; Dennis van der Meer, MSc; Barbara Franke, PhD; Jaap Oosterlaan, PhD; Jan K. Buitelaar, MD, PhD; Stephen V. Faraone, PhD; Pieter J. Hoekstra, MD, PhD

This article is discussed in an editorial by Dr. Philip Shaw on page xx.

Supplemental material cited in this article is available online.

Accepted June 2, 2015

This article was reviewed under and accepted by ad hoc editor Daniel S. Pine, MD.

Ms. Schweren, Drs. Hartman and Hoekstra, and Mr. van der Meer are with University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Drs. Heslenfeld and Oosterlaan are with VU University Amsterdam, The Netherlands. Drs. Franke and Buitelaar are with Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. Dr. Buitelaar is also with Karakter Child and Adolescent Psychiatry University Centre Nijmegen. Dr. Faraone is with State University of New York Upstate Medical University, Syracuse, New York.

This work was supported by National Institutes of Health Grant R01MH62873, Netherlands Organization for Scientific Research (NOW) Large Investment Grant 1750102007010, ZonMW Priority Medicines for Children Grant 113202005, as well as grants from Radboud University Nijmegen Medical Center, University Medical Center Groningen and Accare, and VU University Amsterdam.

Dr. Hartman served as the statistical expert for this research.

Disclosure: Dr. Buitelaar has been in the past 3 years a consultant to/member of advisory board of/and/or speaker for Janssen Cilag BV, Eli Lilly and Co., Shire, Novartis, Lundbeck, and Servier. He is not an employee of any of these companies, or a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, or royalties. Dr. Faraone has received consulting income, travel expenses, and/or research support from, and/or has served on the advisory board for Pfizer, Ironshore, Shire, Akili Interactive Labs, CogCubed, Alcobra, VAYA Pharma, Neurovance, Impax, NeuroLifeSciences, and research support from the National Institutes of Health (NIH). His institution (SUNY) has US patent US20130217707 A1 for the use of

sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he has received consulting fees or served on advisory boards or participated in continuing medical education programs sponsored by Shire, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer, and Eli Lilly and Co. He has received royalties from books published by Guilford Press (*Straight Talk about Your Child's Mental Health*), Oxford University Press (*Schizophrenia: The Facts*), and Elsevier (*ADHD: Non-Pharmacologic Treatments*). Dr. Hoekstra has been a paid consultant to Shire and Eli Lilly and Co. Drs. Hartman, Heslenfeld, Franke, Oosterlaan, Ms. Schweren, and Mr. van der Meer report no biomedical financial interests or potential conflicts of interest.

Correspondence to Lizanne Schweren, MSc, University Medical Center Groningen, Department of Psychiatry, Huispostcode CC10, 9700 VB Groningen, The Netherlands; email: l.j.s.schweren@umcg.nl.

**ABSTRACT**

**Objective:** Attention-deficit/hyperactivity disorder (ADHD) has been associated with widespread changes in cortical thickness (CT). Findings have been inconsistent, however, possibly due to age differences between samples. Cortical changes have also been suggested to be reduced or disappear with stimulant treatment. We investigated differences in CT between adolescents/young adults with and without ADHD in the largest ADHD sample to date, the NeuroIMAGE sample. Second, we investigated how such differences were related to age and stimulant treatment.

**Method:** Participants (ADHD=306; healthy controls=184, 61% male, 8-28 years old, mean age=17) underwent structural magnetic resonance imaging. Participants and pharmacies provided detailed information regarding lifetime stimulant treatment, including cumulative intake and age of treatment initiation and cessation. Vertex-wise statistics were performed in Freesurfer, modeling the main effect of diagnosis on CT and its interaction with age. Effects of stimulant treatment parameters on CT were modeled within the sample with ADHD.

**Results:** After correction for multiple comparisons, participants with ADHD showed decreased medial temporal CT in both left ( $p_{\text{cluster}}=.008$ ) and right ( $p_{\text{cluster}}=.038$ ) hemispheres. These differences were present across different ages and were associated with symptoms of hyperactivity and prosocial behavior. There were no age-by-diagnosis interaction effects. None of the treatment parameters predicted CT within ADHD.

**Conclusion:** Individuals with ADHD showed thinner bilateral medial temporal cortex throughout adolescence and young adulthood compared to healthy controls. We found no association between CT and stimulant treatment. The cross-sectional design of the current study warrants cautious interpretation of the findings.

**Keywords:** ADHD, stimulant treatment, cortical thickness, long-term effects, MRI

## INTRODUCTION

Magnetic resonance imaging (MRI) has revealed structural and functional brain changes associated with attention-deficit/hyperactivity disorder (ADHD)<sup>1-3</sup>. Surface-based reconstruction of the cortical sheet allows quantification of different features of cortical structure, including volume, thickness, surface area, and curvature. Such features may represent distinct developmental processes having separate developmental trajectories<sup>4</sup>. Changes in different features may be associated with distinct forms of psychopathology<sup>5</sup>. Volumetric studies have consistently reported global cortical volume reduction in individuals with ADHD<sup>2,6</sup>. Widespread reductions of cortical thickness (CT) have also been implicated in ADHD. Children and adults with ADHD have shown decreased CT in frontal cortex<sup>7-12</sup>, inferior and superior parietal cortex<sup>10-12</sup>, temporal pole, and medial temporal cortex<sup>11,13</sup>. However, patterns of ADHD-related cortical changes differ widely across studies. There have been multiple reports of increased rather than decreased CT in individuals with ADHD<sup>14,15</sup>, and other studies have found no association between CT and clinical features of ADHD<sup>8,12</sup>.

Discrepant patterns of CT changes in ADHD between studies may result from age differences in groups under study. ADHD often persists into adulthood<sup>16</sup>, typically showing reduced hyperactivity but persistent inattention throughout adolescence. In typical development, CT increases during childhood to reach its peak in early adolescence, after which it decreases again. The “maturational delay” hypothesis of ADHD proposes that CT changes observed in children with ADHD reflect the ADHD group lagging behind the typically developing group and reaching peak CT at a later age<sup>17</sup>. As they grow older, adolescents with ADHD are proposed to “catch up” with their unaffected peers, resulting in fewer or no cortical changes along with a decline in clinical symptoms at later age (remission). The hypothesis is supported by an impressive longitudinal sample of children and adolescents, with an average age of twelve<sup>17</sup>. A substantial proportion of children with ADHD, however, continues to have symptoms in late adolescence and adulthood<sup>18</sup>. Differences in CT in adults with ADHD have also been reported<sup>14,15</sup>, suggesting that individuals with persistent ADHD do not show cortical normalization during late adolescence. Unfortunately, the majority of studies focused on either children or adults, and the development of CT in (late) adolescent ADHD has not extensively been documented. One cross-sectional study found both increases and decreases in CT in older adolescents/young adults with ADHD<sup>14</sup>. Zooming in on the late adolescent phase could aid in further elaboration of cortical development in ADHD.

A substantial proportion of individuals with ADHD are prescribed stimulants. MRI studies investigating the effect of methylphenidate treatment on brain volume and function in children with ADHD have suggested at least partially normalizing effects<sup>1,2,19,20</sup>. Very few have studied the effect of stimulants on CT. In a longitudinal study, Shaw et al.<sup>21</sup> showed normalized developmental trajectories of CT in stimulant-treated but not in non-treated children with ADHD. Treatment effects were local rather than global, affecting CT in the left dorsolateral prefrontal cortex, and right motor and posterior parietal cortex. By contrast, other studies have reported greater CT abnormalities in previously medicated patients<sup>12</sup> or observed no differences between stimulant-naïve and stimulant-treated patients<sup>10</sup>.

The investigation of long-term treatment effects in pediatric groups is complex. Long-term effects (spanning multiple years) may only be assessed in observational studies in which individuals with ADHD have not been randomized over stimulant and non-stimulant treatment. This creates the possibility of confound by indication, i.e. non-stimulant-treated cases may be less severe or may differ from stimulant-treated cases in other ways. An advantage of observational studies, however, is that study samples are typically representative of the study population. To investigate stimulant treatment effects on brain structure, “treated” and “untreated” individuals with ADHD are typically compared. However, this distinction is rather crude and neglects between-subject variation in treatment history. Whereas some classify past users as “treated”<sup>21</sup>, others may classify them as “untreated”<sup>22</sup> or exclude such participants<sup>23</sup>. Investigating treatment heterogeneity in more detail may reveal mechanisms by which stimulant treatment may affect brain structure.

In the current study, we compared CT in a large sample of adolescents/young adults with ADHD (n=306) to that of a healthy control sample (n=184). Further, the linear and non-linear effects of age on changes in CT associated with ADHD (if any) were investigated. Last, we tested the effect of multiple well-defined stimulant treatment parameters. The current study adds to the previous volumetric findings of our group with ADHD being associated with global rather than local volume reductions<sup>6</sup>. Other neuroimaging studies based on the same sample investigated volumetric features,<sup>24–26</sup> structural connectivity,<sup>27–29</sup> or functional MRI.<sup>30–33</sup> To the best of our knowledge, CT has not previously been studied in an ADHD sample of this size.

## METHOD

### *Participants*

Participants were selected from the Dutch follow-up phase of the International Multicenter ADHD Genetics (IMAGE) study<sup>34–36</sup>. ADHD diagnosis, ADHD severity, and presence of comorbid disorders were established using an algorithm based on both the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS<sup>37</sup>) and Conners' ADHD questionnaires for parents<sup>38</sup>, teachers<sup>39</sup>, and adult participants<sup>40</sup>. See <sup>41</sup> and Supplement 1 (available online) for more details and relevant publications regarding the sample and diagnostic algorithm. IQ was estimated from the subtests "vocabulary" and "block design" of the Wechsler Intelligence Scale for Children – Version III<sup>42</sup> (participants  $\leq 16$  years old) or the Wechsler Adult Intelligence Scale – Version III<sup>43</sup> (participants  $> 16$  years old). The subtest "digit span" was administered as an indication of working memory capacity. In addition, the Strengths and Difficulties Questionnaire for Children (CSDQ) was administered.<sup>44</sup> Socioeconomic status (SES) was calculated as the average (of both parents) number of years of education. Participants withheld use of psychoactive drugs for 48 hours prior to their visit. Informed consent was signed by all participants and parents (parents signed informed consent for participants  $< 12$  years old). Testing took place at the University Medical Center of either Amsterdam or Nijmegen. The study was approved by the local ethical committee. The final sample consisted of 306 participants with ADHD and 184 healthy control participants between the ages of 8.3 and 27.8 years old ( $M=17.05$ ,  $SD=3.33$ ).

#### *Assessment of medication history*

Lifetime medication transcripts from pharmacies were available for 74% and covered lifespan for 25% of participants with ADHD. In addition, a questionnaire was administered to all participants and parents assessing lifetime history of psychoactive medication. When pharmacy transcripts did not fully cover the self-reported treatment period, medication parameters of the missing period(s) were calculated from the questionnaire data and were added to the measures derived from the pharmacy. Retrospective assessment of ADHD medication has shown good to excellent concordance between parent- and physician-report, even after multiple years.<sup>45</sup> The following indices of stimulant treatment (methylphenidate immediate/extended release and dexamphetamine preparations) were calculated: history of treatment (stimulant-exposed vs. stimulant-naïve); start age; stop age; median age of exposure (age in years at the median of all exposed days); treatment duration corrected for age (treatment duration divided by [age minus the minimum start-age within the sample, i.e. age 2.3]); mean daily dose (average dose in mg for all exposed days; dexamphetamine dose was multiplied by two); cumulative intake corrected for age (corrected



treatment duration multiplied by mean daily dose); and time since last treatment (age minus stop age). For stimulant-naïve patients, mean daily dose, treatment duration, and cumulative intake were zero; start age was imputed as the participant's age at scan (mimicking late initiation), and stop age was imputed as age 2.3 (mimicking early cessation).

#### *MRI acquisition and analysis*

MRI data was acquired at 1.5T on a Siemens Sonata scanner at the University Medical Center in Amsterdam, and on a Siemens Avanto scanner in Nijmegen, with an identical 8-channel phased array coil and identical acquisition parameters. There were no major hardware upgrades on either of the scanners during the study. Comparability of MRI data from the two sites has extensively been described elsewhere<sup>41</sup>. Scanning parameters and quality assurance procedures are described in Supplement 1, available online. Cortical reconstruction was performed with Freesurfer (<http://surfer.nmr.mgh.harvard.edu/>)<sup>46–48</sup>. Freesurfer is an automated technique to create a 3D reconstruction of the cortical sheet that uses both intensity and continuity information, with good test-retest reliability across scanner stations<sup>49</sup>. CT was calculated for each vertex on the reconstructed cortical sheet and defined as the closest distance from the gray/white boundary to the gray/CSF boundary<sup>50</sup>. Cortical surface area, used in post hoc analyses, was measured at the geometric middle between the inner and outer cortical surfaces. A 10mm full width at half maximum surface-based smoothing kernel was applied. Average CT per participant was calculated across all vertices. Total brain volume was calculated as the sum of Freesurfer estimated total grey and white matter volume.

#### *Data analysis*

Statistical modeling was performed with the glmfit-tool embedded in Freesurfer, and in the second instance in SPSS version 20.0.0.2<sup>51</sup>. The effects of diagnostic group (healthy controls vs. participants with ADHD) and stimulant exposure (stimulant-exposed vs. stimulant-naïve) on CT were analyzed in a linear main effects model including gender, scanner location, and SES as covariates, and age and age<sup>2</sup> as optional per-vertex covariates. Optimal modeling of age as a covariate across the cortex was obtained in a two-step approach: First, between-group differences were evaluated with both age and age<sup>2</sup> in the model in all vertices where age<sup>2</sup> significantly contributed to the prediction of CT. Second, in all other vertices, age was kept in the model only where it significantly contributed to the prediction of CT. As a result, each vertex contained either a quadratic, a linear, or no effect of age (Figure S2, available online). IQ was not added as a covariate in the primary analyses, since we consider lower IQ to be part of

the ADHD phenotype<sup>52</sup>. In two additional vertex-wise models, we tested age-by-diagnosis and age<sup>2</sup>-by-diagnosis interactions.

Comparing stimulant-exposed to stimulant-naïve participants allowed detection of between-group differences of medium effect size ( $n_{\text{EXPOSED}}=270$ ,  $n_{\text{NAIVE}}=36$ ; two-tailed  $\alpha=0.05$ , power=0.80, smallest detectable Cohen's  $d$  effect size=0.50). We further investigated treatment effects by vertex-wise linear modeling of continuous treatment variables within the ADHD sample, i.e. treatment duration corrected for age, mean daily dose, cumulative intake corrected for age, start age, stop age, median age of exposure, and time since last treatment. These parameters were initially tested in seven separate models, predicting CT with gender, scanner location, SES, age, and age<sup>2</sup> as covariates (Bonferroni correction, cluster-wise  $\alpha/7$ ), and then simultaneously for those treatment parameters significantly predicting CT. Unlike in the case-control analyses, linear and quadratic age-terms were included for each vertex, as they were expected to be correlated with the predictor variables. With this approach, regression coefficients of small to medium effect size could be detected ( $n_{\text{TOTAL}}=290$ ; per vertex: two-tailed  $\alpha=0.007$ , power=0.80, smallest detectable Cohen's  $f^2$  effect size =0.067).

We applied Monte Carlo simulation testing (10,000 iterations, vertex-wise threshold  $p<.01$ , cluster-wise threshold  $p<.05$ ) to correct for multiple comparisons. Within each significant cluster, mean CT and surface area were extracted for each participant in standard space to perform post hoc and sensitivity analyses in SPSS. We reported cluster size and  $p$  value from the Monte Carlo simulation testing in Freesurfer, and estimated marginal mean CT per group and Cohen's  $d$  effect size from the SPSS analyses.

Exploratory post hoc analyses were performed to investigate clinical correlates of case-control differences or treatment effects within participants with ADHD ( $n=306$ ). In separate linear mixed effects models, mean CT within each cluster was predicted by number of hyperactivity symptoms, number of inattention symptoms (both derived from the K-SADS interview and Conners' questionnaires), four subscales of the CSDQ (conduct problems, emotional problems, peer problems, and prosocial behavior), working memory capacity (maximum digit span backwards), and IQ. Gender, scanner site, SES, and, if appropriate, age and age<sup>2</sup>, were used as covariates. Second, we tested whether cortical surface area was affected in clusters of significant between-group or treatment effects. Last, for each significant cluster, we tested age-by-diagnosis, age<sup>2</sup>-by-diagnosis, and age-quintiles-by-diagnosis interactions effects.

Sensitivity analyses were performed to investigate the robustness of our findings. First, a random intercept per family was added to the model to account for dependencies among participants from the same family. Further sensitivity analyses entailed repeating each analysis with IQ, average CT, and total brain volume as additional covariates, respectively, and repeating each analysis within subgroups, i.e. within each of the two scanning sites, within boys and girls, within five age quintiles (age<14.05; age=14.06-16.21; age=16.22-18.01; age=18.02-20.04; and age>20.04), within participants who had never received psychoactive treatment other than stimulants, and within participants without any comorbid diagnoses (Table S3, available online). Furthermore, vertex-wise analyses in Freesurfer were repeated with IQ, average CT, and total brain volume as covariates to allow detection of additional clusters (Table S4 and Figure S4, available online).

## RESULTS

### *Demographic and clinical information*

Compared to healthy controls, participants with ADHD were more likely to be male, to have participated in Nijmegen, and had lower SES and IQ (Table 1). Forty-four percent of participants with ADHD were of combined type (n=134). Thirty-three percent of participants with ADHD had a comorbid disorder (n=100), mostly oppositional defiant disorder and/or conduct disorder (n=91, 29.7%), but also tic disorders (n=3, 1.0%) and anxiety/depression (n=11, 3.6%). Eighty-eight percent (n=254) of participants with ADHD had received stimulant treatment at some point in their lives, including immediate-release (n=245, 84.5%) and/or extended-release (n=201, 69.3%) methylphenidate preparations and/or dexamphetamine (n=25, 8.6%). Compared to stimulant-naïve participants, stimulant-exposed participants were more likely to be male, to have participated in Nijmegen, were younger, and had lower IQ and more hyperactivity-impulsivity symptoms (Table 2).

Medication parameters could be calculated for the majority of participants with ADHD (n=290, 94.5%; including 254 stimulant-exposed participants, 87.6%). On average stimulant-exposed participants had received 4.9 years of stimulant treatment (SD=3.19; range 0.05-14.17) corresponding to 33% of their lives. They started stimulant treatment, on average, at age 8.5 (SD=2.75; range 2.30-20.61), and received a mean dose of 34 mg per day (SD=12.47; range 10.00-78.52). Forty-nine percent (n=125) of stimulant-exposed participants had ceased treatment at least three months and on average 1.6 years prior to study participation, with an average stop age of 15.5 years (SD=3.27; range 4.86-23.38). Twenty-eight percent (n=81) of all participants had received psychoactive medication

other than stimulants, including atomoxetine (n=39, 13.5%), clonidine (n=18, 6.2%), antidepressants (n=16, 5.5%), atypical antipsychotics (n=48, 16.6%), and benzodiazepines/anxiolytics (n=15, 5.2%).

#### *CT in participants with ADHD vs healthy controls*

Participants with ADHD showed decreased CT in the medial temporal cortex in both left (cluster size=468mm<sup>2</sup>;  $p_{\text{CLUSTER}}=.008$ ; Cohen's d effect size=0.443;  $CT_{\text{HC}}=3.323\text{mm}$ ;  $CT_{\text{ADHD}}=3.182\text{mm}$ ) and right hemisphere (cluster size=368mm<sup>2</sup>;  $p_{\text{CLUSTER}}=.038$ ; Cohen's d effect size=0.445;  $CT_{\text{HC}}=3.224\text{mm}$ ;  $CT_{\text{ADHD}}=3.113\text{mm}$ ; Figure 1). These case-control differences were significant after accounting for dependencies among participants from the same family, were present in both testing sites and both genders, remained significant when participants with comorbid diagnoses or psychoactive medication other than stimulants were excluded, and when IQ, total brain volume, and average CT (respectively) were added to the model as additional covariates (Table S3, available online). In vertex-wise analyses with IQ and average CT as an additional covariate, a left superior parietal cluster of increased CT in participants with ADHD reached significance as well (Table S4, and Figure S4, available online). In the primary analyses, the same pattern was observed but failed to reach significance after correction for multiple testing (data not shown).

Age<sup>2</sup> did not contribute to the prediction of CT in either of the medial temporal clusters, and the linear age term contributed in the right but not the left hemisphere cluster (Figure S2, available online). CT of the ADHD and healthy control groups within each cluster was plotted in five age quintiles (Figure 2). The direction of effect remained unchanged in all age groups, and there were no age-by-diagnosis ( $p_{\text{LEFT}}=.137$ ,  $p_{\text{RIGHT}}=.328$ ) or age-quintile-by-diagnosis ( $p_{\text{LEFT}}=.085$ ,  $p_{\text{RIGHT}}=.135$ ) interaction effects. In accordance, we found no age/age<sup>2</sup>-by-diagnosis interaction effects in vertex-wise analyses. There was no between-group difference in cortical surface area within the left ( $p=.241$ ) or right ( $p=.166$ ) cluster. Main effects of gender, site, and SES are in Table S2, available online.

#### *Stimulant exposure*

There were no differences in CT between stimulant-treated and stimulant-naïve participants with ADHD. Treatment duration corrected for age, mean daily dose, cumulative intake corrected for age, start age, stop age, median age of exposure, and time since last treatment did not predict CT within the ADHD sample.

#### *Post hoc analyses: clinical correlates*

Exploratory post-hoc analyses indicated that in participants with ADHD, CT within the left medial temporal cluster was related to number of hyperactivity symptoms ( $\beta=-0.039$ ;  $p=.020$ ), but not to number of inattention symptoms ( $p=.571$ ), conduct problems ( $p=.183$ ), emotional problems ( $p=.200$ ), peer problems ( $p=0.562$ ), prosocial behavior ( $p=.647$ ), working memory capacity ( $p=.651$ ), or IQ ( $p=.730$ ). Within the right medial temporal cluster, CT was related to prosocial behavior ( $\beta=0.031$ ;  $p=.034$ ), but not to symptoms of inattention ( $p=.985$ ), hyperactivity ( $p=.246$ ), conduct problems ( $p=.979$ ), emotional problems ( $p=.971$ ), peer problems ( $p=.768$ ), working memory capacity ( $p=.789$ ), or IQ ( $p=.817$ ).

## DISCUSSION

The current study investigated CT among adolescents and young adults with ADHD and its associations with age and stimulant treatment. We found bilateral decreased medial temporal CT in participants with ADHD compared to healthy control participants. These differences were present across different ages, were not accompanied by changes in cortical surface area, were not driven by global brain changes, and were associated with symptoms of hyperactivity and prosocial behavior. Despite having the largest ADHD sample to date with substantial within-subject treatment variability, we found no association between CT and stimulant treatment history.

Reduced CT in medial temporal regions, including the hippocampus, amygdala, and parahippocampal cortex, has previously been reported in pediatric<sup>12,53,54</sup> and adult<sup>11</sup> ADHD groups. Smaller medial temporal volumes have been associated with impaired response inhibition in individuals with ADHD<sup>55</sup>, and structural changes of the hippocampus and amygdala have been associated with emotional dysregulation<sup>56,57</sup>. In a volumetric study of the current sample, a decrease in overall grey matter volume but no changes in hippocampal or amygdalar volumes were detected in participants with ADHD.<sup>6</sup> Discrepant findings may be expected, however, since cortical volume is determined by cortical thickness as well as other parameters (i.e., surface area and gyrification). In addition, analyses of regional cortical volumes (including the hippocampus) in the volumetric study were corrected for global brain changes. Smaller hippocampal volumes may have been masked by the reduction in total brain volume in participants with ADHD<sup>6</sup>. In the current study, adding global brain measures did not change our findings, suggesting that decreased medial temporal CT may not be related to global changes. Our findings add to the growing body of evidence suggesting that regions outside the frontal-striatal circuits may be important in the pathophysiology of ADHD<sup>58</sup>. Our exploratory and preliminary post hoc analyses suggest a link between left medial temporal CT and

hyperactivity symptoms, a core feature of ADHD. The clinical relevance of decreased medial temporal CT is to be further elaborated in future studies, in which hyperactivity and prosocial behavior but also typical medial temporal functions such as memory should be addressed.

The current study being cross-sectional, any findings regarding developmental changes or age effects should be interpreted with caution. Nevertheless, our study provides several interesting findings regarding age and ADHD. First, both clusters of case-control difference occurred (at least partially) in regions where CT was not related to age (Figure 2). In most other vertices, CT decreases with increasing age (Figure S2, available online). Case-control differences thus occur in the absence of developmental changes in CT. Second, we found no age-by-diagnosis or age<sup>2</sup>-by-diagnosis interaction effects. Thus, the medial temporal case-control differences are equally driven by younger and older participants. The developmental delay hypothesis proposes that, later in development, some children with ADHD “catch up” with their typically developing peers<sup>17</sup>, resulting in smaller cortical abnormalities accompanied by (at least partial) clinical remission. This hypothesis could not be tested in the current study, since no cases of remittent ADHD were included. We emphasize again the cross-sectional nature of the current study. As a group, the older participants with ADHD may differ from the younger ones. A sizeable portion of participants within the younger ADHD groups may remit during adolescence, whereas this has not occurred in the older ADHD groups. This more heterogeneous composition of the younger age groups may have masked any age-by-diagnosis interaction effects. There is a clear need for long-term longitudinal studies to characterize cortical development associated with persistence and remission of ADHD during late adolescence/young adulthood.

Despite having sufficient power to detect even small effects, we found no associations between stimulant treatment and CT. Any treatment parameter, regardless of its correlations with the other parameters, would have shown its individual effect (if any) in our initial approach of modeling each parameter separately. The absence of stimulant treatment effects has two implications for our findings. First, it aids the interpretation of the case-control differences. As the ADHD sample consisted largely of stimulant-exposed participants with an average treatment duration of almost five years, any case-control differences we observed may have been the result of stimulant treatment rather than associated with the ADHD phenotype. Two recent studies both reported hippocampal volume reduction in adults with ADHD who had during childhood been treated with stimulants, but not in stimulant-naïve adults with ADHD<sup>23,56</sup>. The lack of association between stimulant treatment and CT within our ADHD group, however, renders this explanation less plausible.

Second, our findings do not support with the hypothesis of CT normalization with stimulant treatment. Most previous studies suggesting structural normalization with stimulant treatment reported cortical volume rather than thickness, of which two recent studies found evidence in meta-regression analyses<sup>1,2</sup>. In one study, development of CT over time was found to be normalized in participants with ADHD who received stimulant-treatment (n=24) compared to those who did not (n=19). These effects were confined to specific brain regions, including the left dorsolateral prefrontal cortex<sup>21</sup>. In a larger study of the same group, however, no stimulant treatment effects were found<sup>9</sup>. We found no evidence of stimulant treatment being associated with CT. Possibly, long-term stimulant treatment affects cortical volume but not thickness. Long-term treatment effects across different cortical features are an interesting opportunity for future studies.

The current study had several strengths. First, our sample comprised older adolescents and young adults, an age group that has received very little attention in previous studies. Second, as pediatric long-term treatment effects cannot be studied in randomized clinical trials, the current study took advantage of its observational nature. This resulted in a large and representative sample, allowing a detailed investigation of between-subject variation in treatment history. Third, access to pharmacy records allowed exact quantification of lifetime stimulant exposure. This extent of detail has rarely been accomplished in previous studies. Our study had limitations too. The study was cross-sectional. An optimal design to investigate long-term outcomes would be longitudinal and include a pre-treatment measurement. In accordance, an optimal study design would include individuals with remitted ADHD as well. Second, few participants with ADHD were naïve to stimulants, and the average treatment duration of the ADHD sample was relatively long. Future studies of treatment effects would benefit from targeted inclusion of additional stimulant-naïve individuals. Third, the large sample size did not allow manual editing of the Freesurfer segmentations, which may have affected reconstruction of the cortical surface especially in the anterior temporal lobes. However, we expect such distortions, if any, to be small and randomly distributed across the participant groups.

In conclusion, we found reduced CT in bilateral medial temporal cortex in youths with ADHD compared to healthy controls. There were no age-by-diagnosis interaction effects. These findings suggest ADHD-related changes in CT existing throughout adolescence and young adulthood, and add to our prior report of overall grey matter volume reduction. In the largest ADHD sample to date, we found no evidence that CT was affected by stimulant

treatment. Our cross-sectional findings suggest the importance of medial temporal regions in adolescent ADHD, and highlight the need for longitudinal studies of ADHD extending into late adolescence and young adulthood.

## REFERENCES

1. Frodl T, Skokauskas N. Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects. *Acta Psychiatr Scand*. 2012;125(2):114–126.
2. Nakao T, Radua J, Rubia K, Mataix-Cols D. Gray matter volume abnormalities in ADHD: voxel-based meta-analysis exploring the effects of age and stimulant medication. *Am J Psychiatry*. 2011;168:1154–63.
3. Bush G, Valera EM, Seidman LJ. Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions. *Biol Psychiatry*. 2005;57(11):1273–84.
4. Raznahan A, Shaw P, Lalonde F, et al. How does your cortex grow? *J Neurosci*. 2011;31(19):7174–7.
5. Shaw P, Malek M, Watson B, Sharp W, Evans A, Greenstein D. Development of cortical surface area and gyrification in attention-deficit/hyperactivity disorder. *Biol Psychiatry*. 2012;72(3):191–7.
6. Greven CU, Bralten J, Mennes M, et al. Developmentally Stable Whole-Brain Volume Reductions and Developmentally Sensitive Caudate and Putamen Volume Alterations in Those With Attention-Deficit/Hyperactivity Disorder and Their Unaffected Siblings. *JAMA psychiatry*. 2015;72:490-9.
7. Almeida LG, Ricardo-Garcell J, Prado H, et al. Reduced right frontal cortical thickness in children, adolescents and adults with ADHD and its correlation to clinical variables: a cross-sectional study. *J Psychiatr Res*. 2010;44(16):1214–23.
8. Yang XR, Carrey N, Bernier D, Macmaster FP. Cortical Thickness in Young Treatment-Naive Children With ADHD. *J Atten Disord*. 2012.
9. Shaw P, Malek M, Watson B, Greenstein D, de Rossi P, Sharp W. Trajectories of cerebral cortical development in childhood and adolescence and adult attention-deficit/hyperactivity disorder. *Biol Psychiatry*. 2013;74(8):599–606.
10. Hoekzema E, Carmona S, Ramos-Quiroga JA, et al. Laminar thickness alterations in the fronto-parietal cortical mantle of patients with attention-deficit/hyperactivity disorder. *PLoS One*. 2012;7(12):e48286.



11. Proal E, Reiss PT, Klein RG, et al. Brain Gray Matter Deficits at 33-Year Follow-up in Adults With Attention-Deficit/Hyperactivity Disorder Established in Childhood. *Arch Gen Psychiatry*. 2011;68(11):1122–1134.
12. Narr KL, Woods RP, Lin J, et al. Widespread cortical thinning is a robust anatomical marker for attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry*. 2009;48(10):1014–22.
13. Langevin LM, MacMaster FP, Dewey D. Distinct patterns of cortical thinning in concurrent motor and attention disorders. *Dev Med Child Neurol*. 2015;57:257–64.
14. Almeida Montes LG, Prado Alcántara H, Martínez García RB, De La Torre LB, Avila Acosta D, Duarte MG. Brain Cortical Thickness in ADHD: Age, Sex, and Clinical Correlations. *J Atten Disord*. 2013;17:641–54.
15. Duerden EG, Tannock R, Dockstader C. Altered cortical morphology in sensorimotor processing regions in adolescents and adults with attention-deficit/hyperactivity disorder. *Brain Res*. 2012;1445:82–91.
16. Copeland WE, Adair CE, Smetanin P, et al. Diagnostic transitions from childhood to adolescence to early adulthood. *J Child Psychol Psychiatry*. 2013;54(7):791–9.
17. Shaw P, Eckstrand K, Sharp W, et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. *Proc Natl Acad Sci U S A*. 2007;104(49):1–6.
18. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. *Psychol Med*. 2006;36(2):159–65.
19. Spencer TJ, Brown A, Seidman LJ, et al. Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies. *J Clin Psychiatry*. 2013;74(9):902–17.
20. Rubia K, Alegria AA, Cubillo AI, Smith AB, Brammer MJ, Radua J. Effects of Stimulants on Brain Function in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. *Biol Psychiatry*. 2014;76:616–28.
21. Shaw P, Sharp WS, Morrison M, et al. Psychostimulant treatment and the developing cortex in attention deficit hyperactivity disorder. *Am J Psychiatry*. 2009;166(1):58–63.

22. Amico F, Stauber J, Koutsouleris N, Frodl T. Anterior cingulate cortex gray matter abnormalities in adults with attention deficit hyperactivity disorder: a voxel-based morphometry study. *Psychiatry Res.* 2011;191(1):31–5.
23. Onnink AM, Zwiers MP, Hoogman M, et al. Brain alterations in adult ADHD: Effects of gender, treatment and comorbid depression. *Eur Neuropsychopharmacol.* 2014;24:397-409.
24. Schwenen LJS, Hartman CA, Zwiers MP, et al. Combined stimulant and antipsychotic treatment in adolescents with attention-deficit/hyperactivity disorder: a cross-sectional observational structural MRI study [epub ahead of print]. *Eur Child Adolesc Psychiatry.* 2014.
25. Van der Meer D, Hoekstra PJ, Zwiers M, et al. Brain Correlates of the Interaction Between 5-HTTLPR and Psychosocial Stress Mediating Attention Deficit Hyperactivity Disorder Severity [epub ahead of print]. *Am J Psychiatry.* 2015 May 22: appiajp201514081035.
26. O'Dwyer L, Tanner C, van Dongen E V, et al. Brain volumetric correlates of autism spectrum disorder symptoms in attention deficit/hyperactivity disorder. *PLoS One.* 2014;9(6):e101130.
27. Van Ewijk H, Heslenfeld DJ, Zwiers MP, et al. Different Mechanisms of White Matter Abnormalities in - Deficit/Hyperactivity Disorder: A Diffusion Tensor Imaging Study. *J Am Acad Child Adolesc Psychiatry.* 2014;53(7):790–799.e3.
28. Van Ewijk H, Groenman AP, Zwiers MP, et al. Smoking and the developing brain: altered white matter microstructure in attention-deficit/hyperactivity disorder and healthy controls. *Hum Brain Mapp.* 2015;36(3):1180–9.
29. Franck W, Zwiers MP, Mennes M, et al. White matter microstructure and developmental improvement of hyperactive/impulsive symptoms in Attention-Deficit/Hyperactivity Disorder [epub ahead of print]. *J Child Psychol Psychiatry.* 2015. DOI: 10.1111/jcpp.12379.
30. Pruim RHR, Mennes M, van Rooij D, Llera A, Buitelaar JK, Beckmann CF. ICA-AROMA: A robust ICA-based strategy for removing motion artifacts from fMRI data. *Neuroimage.* 2015;112:267–277.
31. Pruim RHR, Mennes M, Buitelaar JK, Beckmann CF. Evaluation of ICA-AROMA and alternative strategies for motion artifact removal in resting state fMRI. *Neuroimage.* 2015;112:278–287.
32. Van Rooij D, Hartman CA, Mennes M, et al. Altered neural connectivity during response inhibition in adolescents with attention-deficit/hyperactivity disorder and their unaffected siblings. *NeuroImage Clin.* 2015;7:325–35.

33. Van Rooij D et al. D. Neural activation patterns in inferior frontal areas during response inhibition distinguish adolescents with ADHD, their unaffected siblings, and healthy controls. *Biol Psychiatry*. 2015;in press.
34. Müller UC, Asherson P, Banaschewski T, et al. The impact of study design and diagnostic approach in a large multi-centre ADHD study: Part 2: Dimensional measures of psychopathology and intelligence. *BMC Psychiatry*. 2011;11:55.
35. Müller UC, Asherson P, Banaschewski T, et al. The impact of study design and diagnostic approach in a large multi-centre ADHD study. Part 1: ADHD symptom patterns. *BMC Psychiatry*. 2011;11:54.
36. Rommelse NN, Altink ME, Martin NC, et al. Neuropsychological measures probably facilitate heritability research of ADHD. *Arch Clin Neuropsychol*. 2008;23(5):579–591.
37. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. *J Am Acad Child Adolesc Psychiatry*. 1997;36:980-8.
38. Conners CK, Sitarenios G, Parker JDA, Epstein JN. The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. *J Abnorm Child Psychol*. 1998;26(4):257–268.
39. Conners CK, Sitarenios G, Parker JDA, Epstein JN. Revision and restandardization of the Conners' Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity. *J Abnorm child Psychol*. 1998;26(4):279–291.
40. Conners CK, Erhardt D, Sparrow AP. *Conner's Adult ADHD Rating Scales: CAARS*. North Tonawanda, NY: Multi-Health Systems; 1999.
41. Von Rhein D, Mennes M, van Ewijk H, et al. The NeuroIMAGE study: a prospective phenotypic, cognitive, genetic and MRI study in children with attention-deficit/hyperactivity disorder. Design and descriptives. *Eur Child Adolesc Psychiatry*. 2015;24:265-81.
42. Wechsler. *WISC-III Handleiding*. London: The Psychological Corporation; 2002.
43. Wechsler. *WAIS-III Nederlandstalige bewerking. Technische handleiding*. London: The Psychological Corporation; 2000.

44. Hartman CA, Luteijn E, Serra M, Minderaa R. Refinement of the Children's Social Behavior Questionnaire (CSBQ): an instrument that describes the diverse problems seen in milder forms of PDD. *J Autism Dev Disord.* 2006;36(3):325–42.
45. Kuriyan AB, Pelham WE, Molina BSG, Waschbusch DA, Sibley MH, Gnagy EM. Concordance between parent and physician medication histories for children and adolescents with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol.* 2014;24(5):269–74.
46. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. *Neuroimage.* 1999;9(2):179–194.
47. Fischl B, Salat DH, van der Kouwe A, et al. Sequence-independent segmentation of magnetic resonance images. *Neuroimage.* 2004;23 suppl 1:s69–s84.
48. Fischl B, Sereno MI, Dale AM. Cortical Surface-Based Analysis II: Inflation, Flattening, and a Surface-Based Coordinate System. *Neuroimage.* 1999;9(2):195–207.
49. Han X, Jovicich J, Salat D, et al. Reliability of MRI-derived measurements of human cerebral cortical thickness: the effects of field strength, scanner upgrade and manufacturer. *Neuroimage.* 2006;32(1):180–94.
50. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. *Proc Natl Acad Sci U S A.* 2000;97(20):11050–11055.
51. IBM. IBM SPSS Statistics for Windows. 2011.
52. Dennis M, Francis DJ, Cirino PT, Schachar R, Barnes MA, Fletcher JM. Why IQ is not a covariate in cognitive studies of neurodevelopmental disorders. *J Int Neuropsychol Soc.* 2009;15(3):331–343.
53. Fernández-Jaén A, López-Martín S, Albert J, et al. Cortical thinning of temporal pole and orbitofrontal cortex in medication-naïve children and adolescents with ADHD. *Psychiatry Res.* 2014;224(1):8–13.
54. Shaw P, Lerch J, Greenstein D, et al. Longitudinal mapping of cortical thickness and clinical outcome in children and adolescents with attention-deficit/hyperactivity disorder. *Arch Gen Psychiatry.* 2006;63(5):540–549.
55. McAlonan GM, Cheung V, Chua SE, et al. Age-related grey matter volume correlates of response inhibition and shifting in attention-deficit hyperactivity disorder. *Br J Psychiatry.* 2009;194(2):123–9.

56. Frodl T, Stauber J, Schaaff N, et al. Amygdala reduction in patients with ADHD compared with major depression and healthy volunteers. *Acta Psychiatr Scand*. 2010;121(2):111–8.
57. Posner J, Siciliano F, Wang Z, Liu J, Sonuga-Barke E, Greenhill L. A multimodal MRI study of the hippocampus in medication-naïve children with ADHD: What connects ADHD and depression? *Psychiatry Res*. 2014;224:112–8.
58. Kobel M, Bechtel N, Specht K, et al. Structural and functional imaging approaches in attention deficit/hyperactivity disorder: does the temporal lobe play a key role? *Psychiatry Res*. 2010;183(3):230–6.

### Figure Captions

**Figure 1:** Regions of significant decrease in cortical thickness (cluster-wise  $p$  value  $< .05$ , corrected for multiple comparisons using Monte Carlo simulation testing) in participants with attention-deficit/hyperactivity disorder (ADHD) compared to healthy controls, indicated in red and projected on the pial surface of a standard brain template (fsaverage). Note: There were no regions of increased cortical thickness in participants with ADHD.

**Figure 2:** Cortical thickness (CT) in participants with attention-deficit/hyperactivity disorder (ADHD) and healthy controls (HC), stratified by age (Q1<14.05y; Q2=14.06–16.21y; Q3=16.22–18.01y; Q4=18.02–20.04y; Q5>20.04y) within the medial temporal clusters of case-control difference. Note: Age-quintile-by-diagnosis interaction effects are not significant. Error bars represent standard deviations.

Table 1. Demographic and Clinical Information of Participants With and Without Attention-Deficit/Hyperactivity Disorder (ADHD)


	HC		ADHD		<i>p</i>
	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>	
Participants	184	37.6	306	62.4	
Male	92	50.0	209	68.3	.001
Amsterdam	116	63.0	135	44.1	.001
	<b>Mean</b>	<b>SD</b>	<b>Mean</b>	<b>SD</b>	
Age	16.77	3.15	17.23	3.43	.138
IQ	106.16	13.75	97.05	15.24	.001
SES	13.33	2.50	11.61	2.23	.001

Note: HC = healthy controls; SES = socioeconomic status.


Table 2. Characteristics of the Exposed and Unexposed Participants With Attention-Deficit/Hyperactivity Disorder

	Exposed		Unexposed		<i>p</i>
	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>	
Participants	270	88.2	36	11.8	
Male	192	71.1	17	47.2	.004
Amsterdam	104	38.5	31	86.1	.001
Combined type	122	45.2	12	33.3	.178
Comorbid disorder	89	33.0	11	30.6	.772
ODD/CD	82	30.4	9	25.0	.508
Tic disorder	3	1.1	0	0.0	.525
Anxiety / Depression	9	3.3	2	5.6	.501
	<b>Mean</b>	<b>SD</b>	<b>Mean</b>	<b>SD</b>	
Age	17.04	3.23	18.61	4.45	.048
IQ	96.42	14.84	101.75	17.43	.049
Number of symptoms	13.36	2.93	11.55	3.13	.001
Inattentive	7.34	1.71	6.75	1.59	.053
Hyperactive-impulsive	6.03	2.30	4.89	2.80	.024
SES	11.60	2.25	11.69	2.12	.813

Note: CD = conduct disorder; ODD = oppositional defiant disorder; SES = socioeconomic status.







## Supplement 1 – Method

### *Description of the IMAGE-NeuroIMAGE Sample*

Three-hundred-thirty-one attention-deficit/hyperactivity (ADHD) families and 153 control families participated in a diagnostic interview, questionnaires, and extensive magnetic resonance imaging (MRI) scanning. The following inclusion criteria applied for all participants in the current study: participants had to be (1) between 8-30 years old at follow-up, (2) of European Caucasian descent, (3) have an IQ  $\geq 70$ , (4) have no diagnosis of epilepsy, general learning difficulties, brain disorders, and known genetic disorders (such as Down syndrome), (5) have no contra indication to MR scanning, and (6) show no incidental findings on the MRI scan. Healthy control participants had to fulfill the following additional criteria: no current or past mental health care utilization, no sibling(s) with any past or current psychiatric diagnosis, and no current or past psychoactive medication use. As recruitment was family-based, multiple members of one family could be included in the same diagnostic group. Unaffected siblings of participants with ADHD were excluded. Previous relevant publications from our group regarding the same sample that are not in the reference list included a study focusing on working memory and another on the risk of developing substance use disorder in relation to stimulant treatment.<sup>1,2</sup>

### *Scanning Parameters and Quality Control Procedures*


Structural MRI acquisition consisted of two T1-weighted 3D MP-RAGE scans (TI = 1,000 ms, TR = 2,730 ms, TE = 2.95 ms, FA = 7°; parallel imaging by generalized autocalibrating partially parallel acquisition [GRAPPA]; 176 sagittal slices, voxel size 1 x 1 x 1 mm, FOV = 256 x 256 x 176 mm). For each participant, the structural acquisition of highest quality was selected by visual inspection,<sup>3</sup> accepting only scans with no/mild distortions. To assure Freesurfer reconstruction quality, the following reconstructions were subjected to visual inspection to detect regions of “flattened” or “spiky” surface and surface wholes: (1) twenty percent (randomly selected) of the sample; (2) all reconstructions based on a structural scan with mild distortions. Reconstructions that did not meet quality criteria were excluded from all analyses; no manual edits were made.

## References

1. Van Ewijk H, Heslenfeld DJ, Luman M, et al. Visuospatial working memory in ADHD patients, unaffected siblings, and healthy controls. *J Atten Disord.* 2014; 18: 369–78.
2. Groenman AP, Oosterlaan J, Rommelse NNJ, et al. Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder. *Br J Psychiatry.* 2013; 203: 112–9.
3. Blumenthal JD, Zijdenbos A, Molloy E, Giedd JN. Motion artifact in magnetic resonance imaging: implications for automated analysis. *Neuroimage.* 2002; 16: 89–92.

**Supplement 2 – Covariates**

**Figure S2.** Clusters of significant main effects of the linear and quadratic age terms (light blue and dark blue, respectively; corrected for multiple comparisons using Monte Carlo simulation testing). Note: Increasing age was associated with decreasing cortical thickness. There were no regions of increasing cortical thickness with increasing age. The two medial temporal clusters of case-control difference are delineated in red.



**Table S2. Gender, Scanner, and Socioeconomic Status (SES)**

Covariate	Direction	Hemi	Region	Size	T <sub>MAX</sub>	P <sub>CLUSTER</sub>
Gender	Boys > Girls	R	Lingual cortex	522.67	-4.578	.00480
		L	Precentral cortex	374.89	-6.175	.03100
		R	Insula	439.79	-5.401	.01300
		R	Superior temporal cortex	475.71	-4.982	.00820
		L	Middle frontal cortex	353.99	-4.629	.04050
	Girls > Boys	R	Posterior cingulate cortex	499.60	6.114	.00610
		L	Postcentral cortex	577.36	4.980	.00230
		R	Precentral cortex	360.60	3.398	.04190
		R	Inferior parietal cortex	410.96	5.105	.01930
		R	Medial orbitofrontal	458.62	6.134	.00960
SES	Neg	R	Lateral occipital cortex	434.31	-3.013	.01340
Scanner site	AMS < NIJM	R	Middle temporal cortex	1,196.71	-15.618	.00010
		L	Middle temporal cortex	3,396.30	-17.608	.00010
		R	Middle frontal cortex	7,402.56	-12.716	.00010
		L	Middle frontal cortex	9,300.90	-14.960	.00010
	NIJM < AMS	R	Inferior parietal cortex	529.24	3.065	.00400
		L	Superior parietal cortex	8,971.47	7.844	.00010
		R	Middle frontal cortex	896.99	4.627	.00010
		L	Middle frontal cortex	2,012.35	6.515	.00010
		R	Precuneus cortex	3,257.91	8.543	.00010
		R	Supramarginal cortex	894.47	4.618	.00010

Note: Clusters of significant main effects of covariates gender, scanner site, and SES ( $p_{\text{vertex}}=.01$ ,  $p_{\text{cluster}}=.05$ , corrected for multiple testing), tested in the full model (cortical thickness is predicted by diagnostic status, scanner site, gender, SES, age, and age<sup>2</sup>). AMS = scanner in Amsterdam; L = left; NIJM = scanner in Nijmegen; Neg = negative correlation; P<sub>CLUSTER</sub> = cluster-wise p-value after correction for multiple comparisons; Pos = positive correlation; R = right; Size = cluster size in mm<sup>2</sup>.

## Supplement 3 – Sensitivity Analyses

Table S3. Sensitivity Analyses

	n	LH			RH		
		EMM <sub>HC</sub>	EMM <sub>ADHD</sub>	<i>p</i>	EMM <sub>HC</sub>	EMM <sub>ADHD</sub>	<i>p</i>
<b>Original analyses / all subjects</b>	<b>490</b>	<b>3.323</b>	<b>3.182</b>	<b>.001</b>	<b>3.224</b>	<b>3.113</b>	<b>.001</b>
Within Amsterdam	251	3.347	3.221	.003	3.207	3.136	.028
Within Nijmegen	239	3.306	3.140	.001	3.256	3.092	.001
Within boys	301	3.342	3.191	.001	3.222	3.110	.001
Within girls	189	3.304	3.178	.014	3.238	3.113	.002
Within age < 14.05	99	3.252	3.201	.526	3.198	3.092	.120
Within age 14.05-16.21	98	3.347	3.242	.060	3.278	3.144	.007
Within age 16.21-18.01	98	3.335	3.197	.037	3.211	3.142	.162
Within age 18.01-20.04	97	3.416	3.119	.001	3.304	3.094	.001
Within age > 20.04	98	3.336	3.173	.031	3.156	3.100	.334
Excluding comedication	401	3.326	3.184	.001	3.221	3.117	.001
Excluding comorbidity	389	3.326	3.193	.001	3.224	3.115	.001
Additional covariate: IQ	490	3.321	3.184	.001	3.227	3.112	.001
Additional covariate: TBV	490	3.323	3.183	.001	3.224	3.113	.001
Additional covariate: average CT	490	3.318	3.185	.001	3.223	3.116	.001

Note: Estimated marginal mean cortical thickness in subsamples of healthy control participants and participants with attention-deficit/hyperactivity disorder (ADHD), and associated *p* values within the left and right medial temporal cluster of significant case-control difference. CT = cortical thickness; EMM = estimated marginal mean cortical thickness in mm; HC = healthy control participants; LH = left hemisphere; *p* = cluster-wise *p* value after correction for multiple comparisons; RH = right hemisphere; TBV = total brain volume.


**Supplement 4 – Vertex-Wise Analyses With Additional Covariates (IQ, Total Brain Volume and Average Cortical Thickness)**

**Table S4. Participants With Attention-Deficit/Hyperactivity Disorder (ADHD) Vs. Healthy Control (HC)**

**Participants**

Additional covariate	Region	Cluster size	$p_{\text{CLUSTER}}$	Cohen's d	EMM <sub>HC</sub>	EMM <sub>ADHD</sub>
IQ	L medial temporal	435.07	0.012	0.415	3.355	3.214
	R medial temporal	357.37	0.043	0.436	3.235	3.117
	L superior parietal	359.33	0.037	-0.434	2.091	2.204
Average CT	L medial temporal	440.36	0.006	0.417	3.334	3.199
	R medial temporal	340.71	0.032	0.449	3.229	3.117
	L superior parietal	385.43	0.014	-0.475	2.094	2.200
TBV	L medial temporal	475.00	0.009	0.425	3.349	3.207
	R medial temporal	390.75	0.028	0.419	3.184	3.073

Note: Regions of significant increased and decreased cortical thickness (CT; cluster-wise  $p$  value < .05, corrected for multiple comparisons using Monte Carlo simulation testing), in participants with ADHD compared to healthy control participants, in a statistical model including estimated IQ, total brain volume, or average cortical thickness as an additional covariate. EMM = estimated marginal mean cortical thickness in mm; L = left;  $p_{\text{CLUSTER}}$  = cluster-wise  $p$  value after correction for multiple comparisons; R = right; TBV = total brain volume.



**Figure S4.** Regions of significant decreased cortical thickness in red and increased cortical thickness in blue (cluster-wise  $p$  value  $< .05$ , corrected for multiple comparisons using Monte Carlo simulation testing), in participants with attention-deficit/hyperactivity disorder (ADHD) compared to healthy control participants, in a statistical model including estimated IQ as an additional covariate.